A Phase 2 Study of Enasidenib in IDH2-Mutant Angioimmunoblastic T-Cell Lymphoma
This study is testing a medication called enasidenib to see if it is safe and helpful for people with a specific type of blood cancer called angioimmunoblastic T-cell lymphoma. Researchers want to see how well it works either by itself or combined with another cancer-fighting drug called rituximab.
You might be able to join if you are 18 or older, have a confirmed diagnosis of this specific type of lymphoma with a certain genetic change called an IDH2 mutation, and have tried at least one prior treatment. Your general health, kidney, and liver functions also need to meet certain safety standards.
Participants will receive the study medication, which may include enasidenib alone or paired with rituximab. You will be closely monitored by the medical team with regular health checks and tests to watch how your body and the cancer respond to the treatment.
This study takes place at locations in New Jersey, United States, and is currently active but not actively looking for new participants at this time.
- 1Tests the safety of the drug enasidenib for a specific type of T-cell lymphoma.
- 2Requires participants to have a specific genetic mutation known as IDH2.
- 3The study is currently active in New Jersey but not seeking new patients right now.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.